EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Postoperative Intimal Hyperplasia: Review from My Research

Mitsuhiro Yamamura

International Journal of Angiology · 01.09.2024 · 33 (03) · 135-138

DOI: 10.1055/s-0044-1779300 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Angiology, erschienen am 01.09.2024. Verfasst von Mitsuhiro Yamamura. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Hyogo Medical University, Nishinomiya-city, Hyogo, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postoperative intimal hyperplasia is the major cause of the vein graft occlusion. It is very important to establish an animal model for the start of research. After my vascular surgery residency in Japan, I started my research work on postoperative intimal hyperplasia at the University of Wisconsin-Madison. My research showed that endothelial injury and monocyte infiltration is the key for postoperative intimal hyperplasia, which is very similar to Ross' pathogenesis of atherosclerosis as an inflammatory disease. Focusing on postoperative intimal hyperplasia as an inflammatory disease, especially on tumor necrosis factor-α, FR-167653 (tumor necrosis factor-α suppressive agent, inhibitor of p38 mitogen-activated protein kinase; Fujisawa Pharmaceutical Co., Ltd., Japan) is found to suppress postoperative intimal hyperplasia in a rat model by reducing serum monocyte chemoattractant protein-1 levels. However, FR-167653 is not commercially available today. Because endothelial injury is the first step of postoperative intimal hyperplasia, I investigated whether the free radical scavenger, edaravone (Radicut, Mitsubishi Tanabe Pharma Co., Japan), which alleviates the endothelial injury in vitro, can also suppress postoperative intimal hyperplasia. Moreover, the free radical scavenger edaravone (Radicut®, Mitsubishi Tanabe Pharma Co.) is also found to suppress postoperative intimal hyperplasia, by alleviating endothelial injury. In clinical settings, it is very important to detect postoperative intimal hyperplasia before its establishment. Hepatocyte growth factor is not only a hepatic growth factor but also a vascular endothelial growth factor. Recently, serum hepatocyte growth factor level was found to be a candidate biomarker for postoperative intimal hyperplasia in our rat model.

Schlagwörter

Stichwörter der Autor:innen

endothelial injuryfree radical scavengerhepatocyte growth factormonocyte chemoattractant protein-1monocyte infiltrationpostoperative intimal hyperplasiatumor necrosis factor-α suppressive agent

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, Hyogo Medical University, Nishinomiya-city, Hyogo, Japan.

Zitieren

APA

Yamamura, M. (2024). Postoperative Intimal Hyperplasia: Review from My Research. International Journal of Angiology, 33(03), 135-138. https://doi.org/10.1055/s-0044-1779300

Vancouver

Yamamura M. Postoperative Intimal Hyperplasia: Review from My Research. International Journal of Angiology. 2024;33(03):135-138. doi:10.1055/s-0044-1779300

BibTeX
@article{Yamamura2024,
  author = {Yamamura, Mitsuhiro},
  title = {Postoperative Intimal Hyperplasia: Review from My Research},
  journal = {International Journal of Angiology},
  year = {2024},
  volume = {33},
  number = {03},
  pages = {135--138},
  doi = {10.1055/s-0044-1779300}
}
Kostenlos starten →